ImmunityBio, Inc.

IBRX Nasdaq Healthcare · Biological Products, (No Diagnostic Substances) San Diego, CA immunitybio.com
$7.29
Mkt Cap 7.73B

Biotechnology company developing and commercializing immunotherapy and cell therapy products for cancer, including its approved ANKTIVA treatment.

immunitybio.com ↗Summary by The Compound Family, based on the company’s own website
—
/100 Overall
Calculating score…
Running full analysis
Ready to value this company?
Run a full DCF model with Monte Carlo simulation.
Run DCF Valuation →
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$165.8M
184.8% CAGR
FCF TTM
-$288.1M
-173.8% margin
Running full 6-factor analysis…